Maze Therapeutics (NASDAQ:MAZE) Insider Sells $202,950.00 in Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) insider Atul Dandekar sold 7,500 shares of the company’s stock in a transaction dated Tuesday, September 29th. The stock was sold at an average price of $27.06, for a total transaction of $202,950.00. Following the completion of the sale, the insider directly owned 32,316 shares in the company, valued at approximately $874,470.96. The trade was a 18.84% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Atul Dandekar also recently made the following trade(s):

• On Thursday, September 3rd, Atul Dandekar sold 3,243 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.01, for a total transaction of $84,350.43.
• On Wednesday, September 2nd, Atul Dandekar sold 3,191 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.47, for a total transaction of $84,465.77.
• On Friday, August 28th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The stock was sold at an average price of $27.58, for a total transaction of $206,850.00.
• On Wednesday, July 29th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The shares were sold at an average price of $27.34, for a total transaction of $205,050.00.

Maze Therapeutics Price Performance

Shares of MAZE traded down $0.53 on Thursday, hitting $26.65. The company’s stock had a trading volume of 589,347 shares, compared to its average volume of 665,813. The company has a market capitalization of $1.48 billion, a PE ratio of -10.58 and a beta of 2.17. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.31 and a quick ratio of 18.31. Maze Therapeutics, Inc. has a fifty-two week low of $21.95 and a fifty-two week high of $53.65. The company has a 50 day moving average price of $27.02 and a 200 day moving average price of $28.40.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.76). On average, research analysts anticipate that Maze Therapeutics, Inc. will post -2.72 earnings per share for the current fiscal year.

Institutional Trading of Maze Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MAZE. Squarepoint Ops LLC raised its holdings in Maze Therapeutics by 42.8% during the 2nd quarter. Squarepoint Ops LLC now owns 19,434 shares of the company’s stock worth $580,000 after purchasing an additional 5,822 shares during the last quarter. Frazier Life Sciences Management L.P. boosted its stake in shares of Maze Therapeutics by 10.2% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company’s stock valued at $150,182,000 after purchasing an additional 465,641 shares during the last quarter. AXQ Capital LP grew its position in shares of Maze Therapeutics by 114.1% during the 2nd quarter. AXQ Capital LP now owns 15,193 shares of the company’s stock worth $453,000 after buying an additional 8,098 shares during the period. Braidwell LP acquired a new stake in shares of Maze Therapeutics during the 2nd quarter worth approximately $34,019,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Maze Therapeutics by 4,054.3% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 17,739 shares of the company’s stock worth $529,000 after buying an additional 17,312 shares during the last quarter.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on MAZE shares. BTIG Research restated a “buy” rating and issued a $46.00 target price on shares of Maze Therapeutics in a research note on Tuesday, September 22nd. TD Cowen upgraded shares of Maze Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. Wedbush reiterated an “outperform” rating and set a $48.00 target price on shares of Maze Therapeutics in a research report on Wednesday, September 23rd. Citigroup assumed coverage on shares of Maze Therapeutics in a research report on Wednesday, September 23rd. They set a “buy” rating and a $50.00 target price on the stock. Finally, Wall Street Zen lowered shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Three investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $63.40.

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically driven diseases. The company combines human genetics, functional genomics and drug discovery technologies through its Maze Compass platform to identify disease mechanisms and develop therapies designed to address the underlying causes of disease.

Maze’s lead program, MZE001, is an oral small-molecule inhibitor of glycogen synthase being developed for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles and other tissues.